NNovo Nordisk Read More Novo Nordisk’s new weight loss treatment inferior to tirzepatide 2026-02-27 Novo Nordisk’s latest weight loss treatment, CagriSema, did not meet the primary endpoint of showing non-inferiority compared to…
NNovo Nordisk Read More Novo Nordisk’s triple agonist delivers up to 19.7% weight loss2026-02-26 Novo Nordisk’s triple agonist UBT251 delivered a mean weight loss of 19.7% after 24 weeks in a Phase…